Samlyn Capital’s bluebird bio BLUE Stock Holding History

Samlyn Capital’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,366	Closed	-$3.96M	–	118
2017 Q1	$3.96M	Buy	+3,366	New	+$3.43M	0.09%	127

Other funds holding BLUE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Samlyn Capital's BLUE Position: Q2 2017 in Review

Samlyn Capital sold out of bluebird bio (BLUE) in Q2 2017, closing a stake of 3,366 shares — an estimated $3.96M sold.

Samlyn Capital first reported a position in BLUE in Q1 2017 and held it in 1 quarter. The position peaked at $3.96M in Q1 2017. 241 funds tracked by Wall St. Rank hold BLUE as of Q2 2017.

Samlyn Capital reported no remaining bluebird bio position as of Q2 2017 after selling out during the quarter.
Samlyn Capital sold 3,366 bluebird bio shares in Q2 2017, an estimated $3.96M.
Samlyn Capital first reported a position in bluebird bio in Q1 2017 and held it in 1 quarter.
Samlyn Capital's bluebird bio position peaked at $3.96M in Q1 2017.
241 funds tracked by Wall St. Rank held bluebird bio as of Q2 2017.

Based on Samlyn Capital's 13F filing for Q2 2017, filed 14 Aug 2017.